3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Other hematologic neoplasm
1
NET
1
Myeloid
1
Endocrine
1
Conditions
Myelodysplastic Syndromes
522
Leukemia, Myeloid, Acute
404
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
308
Leukemia
292
Precursor Cell Lymphoblastic Leukemia-Lymphoma
234
Myeloproliferative Disorders
210
Lymphoma, Non-Hodgkin
167
Leukemia, Myelomonocytic, Chronic
156
Leukemia, Lymphocytic, Chronic, B-Cell
147
Hodgkin Disease
142
Primary Myelofibrosis
141
Multiple Myeloma
133
Leukemia, Myeloid, Chronic-Phase
133
Lymphoma
114
Leukemia, Myeloid, Accelerated Phase
96
Blast Crisis
94
Anemia, Refractory, with Excess of Blasts
89
Polycythemia Vera
88
Lymphoma, Follicular
84
Burkitt Lymphoma
81
Lymphoma, Mantle-Cell
80
Myelodysplastic-Myeloproliferative Diseases
78
Lymphoma, B-Cell, Marginal Zone
77
Lymphoma, Large B-Cell, Diffuse
73
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
70
Congenital Abnormalities
70
Neoplasms, Plasma Cell
59
Lymphoma, Large-Cell, Immunoblastic
59
Thrombocythemia, Essential
57
Graft vs Host Disease
57
Interventions
nilotinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplastic Processes
×
Myeloid
×
Clear all
NCT01844765
2021-04-22
DIALOG
Novartis
Phase 2
Completed
59 enrolled
33 charts
1 FDA